Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03875859 · ClinicalTrials.gov registry record · Phase 2
Topical Remetinostat Gel as Neoadjuvant Therapy in Patients With Squamous Cell Carcinoma (SCC)
A Phase 2 study, sponsored by Kavita Sarin.
- Terminated
- Registry status
- Phase 2
- Development phase
- 4
- Enrollment target
NCT03875859 is a Phase 2 study that was terminated before completion, run by Kavita Sarin. The registered enrollment target is 4 participants.
The verdict
NCT03875859, a Phase 2 study, was terminated before completion, sponsored by Kavita Sarin.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 4 participants
- Enrollment target
Study Summary
The primary purpose of this study is to determine if 8 weeks of topical remetinostat applied three times daily will suppress Squamous Cell Carcinoma.
Interventions
- DRUG Remetinostat
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 4 participants |
| Start Date | 2019-12-12 |
| Est. Completion | 2021-01-30 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03875859
The ClinicalTrials.gov registry entry for NCT03875859 describes a study currently listed as terminated, categorized as Phase 2. The registered enrollment target is 4 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Kavita Sarin, which has 2 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Remetinostat is the first listed.
NCT03875859 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03875859 about?
NCT03875859 is a clinical study titled "Topical Remetinostat Gel as Neoadjuvant Therapy in Patients With Squamous Cell Carcinoma (SCC)". The primary purpose of this study is to determine if 8 weeks of topical remetinostat applied three times daily will suppress Squamous Cell Carcinoma.
What is the current status of trial NCT03875859?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 4 participants. The study started on 2019-12-12. Estimated completion is 2021-01-30.
What interventions are being tested in trial NCT03875859?
The interventions under investigation include: Remetinostat (DRUG).
Who is sponsoring clinical trial NCT03875859?
This trial is sponsored by Kavita Sarin, which has 2 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.